Elevance Health, Inc. $ELV Stock: Vest Financial LLC Raises Holdings

Vest Financial LLC increased its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 7.5% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 60,888 shares of the company’s stock after purchasing an additional 4,261 shares during the period. Vest Financial LLC’s holdings in Elevance Health were worth $23,674,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Activest Wealth Management raised its stake in Elevance Health by 146.2% in the third quarter. Activest Wealth Management now owns 64 shares of the company’s stock valued at $25,000 after buying an additional 38 shares during the period. WealthCollab LLC lifted its position in shares of Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after buying an additional 27 shares during the last quarter. Kilter Group LLC acquired a new stake in shares of Elevance Health in the second quarter valued at approximately $28,000. Main Street Group LTD bought a new position in shares of Elevance Health during the 1st quarter worth approximately $39,000. Finally, Elevation Wealth Partners LLC boosted its stake in shares of Elevance Health by 600.0% during the 2nd quarter. Elevation Wealth Partners LLC now owns 105 shares of the company’s stock worth $41,000 after acquiring an additional 90 shares during the period. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Up 2.7%

Shares of ELV stock opened at $445.85 on Friday. The firm has a 50 day moving average price of $407.53 and a two-hundred day moving average price of $390.54. The company has a quick ratio of 1.52, a current ratio of 1.47 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $96.69 billion, a PE ratio of 14.30, a price-to-earnings-growth ratio of 2.12 and a beta of 0.70. Elevance Health, Inc. has a 12-month low of $274.84 and a 12-month high of $450.69.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The company had revenue of $50.44 billion during the quarter, compared to analysts’ expectations of $49.28 billion. During the same quarter in the previous year, the company posted $6.03 earnings per share. The business’s revenue was up .7% on a year-over-year basis. As a group, analysts predict that Elevance Health, Inc. will post 29.00 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be issued a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 1.5%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health’s dividend payout ratio (DPR) is presently 30.58%.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Strong Q3 earnings beat: Adjusted earnings were $6.99 per share, well above the roughly $4.71 analyst consensus and up from $6.03 a year earlier. Revenue of $50.44 billion also exceeded estimates of $49.28 billion, supported by stronger execution across Elevance’s businesses. Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: Higher earnings outlook: Management raised its 2026 adjusted EPS baseline to at least $26.75, with some coverage citing a target of at least $29, and reiterated expectations for at least 12% adjusted EPS growth in 2027 from the higher baseline. Better medical-cost management and disciplined expenses support the upgraded forecast. Elevance lifts 2026 profit forecast on better medical cost management
• Positive Sentiment: Carelon provides growth potential: Carelon’s expansion helped offset pressure in the insurance business. Its cancer program reportedly reduced avoidable inpatient admissions by 15%, while the company sees continued demand for integrated healthcare services. Elevance also appointed Jeff Park as Carelon president, effective December 1, to lead its next growth phase. Elevance Health Names Jeff Park President of Carelon
• Positive Sentiment: Analyst support and shareholder return: Morgan Stanley raised its price target to $449 while retaining an Equal Weight rating. Elevance also declared a quarterly dividend of $1.72 per share, or $6.88 annualized, representing a yield of approximately 1.6%.
• Neutral Sentiment: Valuation has become more demanding: Robert W. Baird raised its target to $406 but kept a Neutral rating, implying limited upside from the recent trading level. The stock has also reached a 52-week high, which may limit near-term gains without additional earnings upgrades.
• Negative Sentiment: Underlying profitability risks remain: Medicaid margins and declining medical membership continue to weigh on Elevance’s Health Benefits segment. While medical-cost trends improved, nine-month operating gain declined, raising questions about how durable the earnings recovery will be. Elevance Health: Better Results, But Not Enough To Buy

Analyst Upgrades and Downgrades

ELV has been the topic of a number of recent analyst reports. Leerink Partners boosted their target price on Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a report on Friday, July 17th. Royal Bank Of Canada raised their price target on Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a report on Thursday. UBS Group raised their price target on Elevance Health from $460.00 to $523.00 and gave the company a “buy” rating in a report on Thursday. Barclays lifted their price objective on shares of Elevance Health from $469.00 to $472.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Sanford C. Bernstein set a $488.00 price objective on shares of Elevance Health in a report on Thursday, July 16th. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $450.29.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.